financial results
The company said clinical revenue drove growth and raised its full-year 2025 guidance to reflect added income from its recent acquisition of clinical lab Pathline.
UPDATE: Labcorp Q1 Revenues Rise 5 Percent
The firm reported on Tuesday that its diagnostics revenues rose 6 percent from a year ago while its biopharma lab services revenues rose almost 2 percent.
The firm said that its overall revenues rose 2 percent year over year and 4 percent on an organic basis with a smaller increase in its life sciences revenues.
The firm's core laboratory revenues declined 1 percent, while molecular laboratory sales were up 4 percent.
Thermo Fisher Scientific Lowers 2025 Adjusted EPS Guidance in Light of Tariffs, US Policy Changes
Premium
The new guidance reflects the impact from China-related tariffs as well as dampening US grant funding, partially offset by the firm's mitigation actions.
Apr 22, 2025
Mar 24, 2025
Lucid Diagnostics Q4 Revenues Rise 20 Percent
Mar 4, 2025
Biodesix Q4 Revenues up 39 Percent
Mar 3, 2025
360Dx Top 30 Drops 9 Percent in February
Feb 28, 2025